Outcome of the Board Meeting of the Company held on 29th May 2026, and submissions of Audited Financial Results for the Quarter and year ended 31.03.2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Brawn Biotech Ltd reported audited full-year results for FY2026 ending 31 March 2026. Total revenue grew 28.6% year-on-year to Rs 1,743.18 Lacs from Rs 1,355.83 Lacs in FY2025. The company swung from a net loss of Rs 179.81 Lacs in the prior year to a net profit of Rs 94.06 Lacs. EPS for the year stood at Rs 3.26 per share (vs -Rs 5.67 in FY2025). The company posted positive operating cash flows of Rs 11.19 Lacs (vs negative Rs 1,978.40 thousands in the prior year), indicating a meaningful turnaround. Trade payables increased significantly to Rs 1.17 Cr, reflecting higher business activity. The statutory auditor (Rajiv Udai & Associates) issued an unmodified (clean) opinion with no qualifications.
The company returned to profitability after two consecutive loss years, with strong revenue growth of nearly 29%. Positive operating cash flow and improved equity (from Rs 336 Lacs to Rs 434 Lacs) signal a financial turnaround. However, the company remains a small-cap pharma firm with modest absolute profits.